Use of an angular transformation for ratio estimation in cost-effectiveness analysis

被引:0
|
作者
Cook, JR [1 ]
Heyse, JF [1 ]
机构
[1] Merck Res Labs, W Point, PA 19486 USA
关键词
D O I
10.1002/1097-0258(20001115)19:21<2989::AID-SIM599>3.0.CO;2-G
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Economic evaluations of medical technologies involve a consideration of both costs and clinical benefits, and an increasing number of clinical studies include a specific objective of assessing cost-effectiveness. These studies measure the trade-off between costs and benefits using the cost-effectiveness ratio (CE ratio), which is defined as the net incremental cost per unit of benefit provided by the candidate therapy. In this gaper we review the statistical methods which have been proposed for estimating 95 per cent confidence intervals for cost-effectiveness ratios. We show that the use of an angular transformation of the standardized ratio stabilizes the variance of the estimated CE ratio, and provides a clearer interpretation of study results. An estimate of the 95 per cent confidence interval for the CE ratio in the transformed scale is easily made using the jack-knife or bootstrap. The available methods are compared using data from a long term study of mortality in patients with congestive heart failure. Copyright (C) 2000 John Wiley & Sons, Ltd.
引用
收藏
页码:2989 / 3003
页数:15
相关论文
共 50 条
  • [21] Prostaglandin analogues for ophthalmic use: a cost-effectiveness analysis
    Lachaine, Jean
    Hodge, William G.
    Steffensen, Isabella
    Murray, Christine
    Barnes, David
    Foerster, Vicki
    Ducruet, Thierry
    Mensinkai, Shaila
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2008, 43 (01): : 33 - 41
  • [22] THE USE OF PERSPECTIVE AND COSTING APPROACHES IN COST-EFFECTIVENESS ANALYSIS
    Kim, D.
    Silver, M.
    Cohen, J. T.
    Ollendorf, D. A.
    Neumann, P. J.
    VALUE IN HEALTH, 2020, 23 : S235 - S235
  • [23] Valuing Health States for Use in Cost-Effectiveness Analysis
    John Brazier
    PharmacoEconomics, 2008, 26 : 769 - 779
  • [24] Cost-effectiveness analysis in surgery: Who will use it and how?
    Rhodes, RS
    Rhodes, P
    SURGERY, 1998, 123 (02) : 119 - 120
  • [25] COST-EFFECTIVENESS ANALYSIS OF USE OF DYDROGESTERONE IN PREMENSTRUAL SYNDROME
    Kolbin, A.
    Vilum, I
    Kurylev, A.
    Balykina, Y.
    Proskurin, M.
    VALUE IN HEALTH, 2014, 17 (07) : A508 - A508
  • [26] STATISTICAL POWER CONSIDERATIONS IN THE USE OF COST-EFFECTIVENESS ANALYSIS
    SACCO, WP
    PROFESSIONAL PSYCHOLOGY, 1982, 13 (05): : 752 - 758
  • [27] COST-EFFECTIVENESS OF ANTIBIOTIC USE
    ALDIS, WL
    COWAN, D
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (23): : 3252 - 3252
  • [28] ESTIMATION OF COST PARAMETERS USING CLAIMS DATABASE FOR USE IN COST-EFFECTIVENESS ANALYSIS OF LUNG CANCER TREATMENT IN JAPAN
    Fujiwara, T.
    Moriwaki, K.
    VALUE IN HEALTH, 2018, 21 : S12 - S12
  • [29] Genetic counseling program in familial breast cancer:: Analysis of its effectiveness, cost and cost-effectiveness ratio
    Balmaña, J
    Sanz, J
    Bonfill, X
    Casado, A
    Rué, M
    Gich, I
    Díez, O
    Sabaté, JM
    Baiget, M
    Alonso, MC
    INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (04) : 647 - 652
  • [30] Does the use of efficacy or effectiveness evidence in cost-effectiveness analysis matter?
    Dilokthornsakul, Piyameth
    Chaiyakunapruk, Nathorn
    Campbell, Jonathan D.
    JOURNAL OF ASTHMA, 2017, 54 (01) : 17 - 23